Evidence map›Paper›PMID 36232835›Full record

ReviewInternational journal of molecular sciences2022

Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?

Julia Sala-Jarque, Karolina Zimkowska, Jesús Ávila, Isidro Ferrer, José Antonio Del Río

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. DnaJs are enriched in tau regulators.International journal of biological macromolecules · 2023
    Article
  4. Article
  5. Review
  6. Molecular Mechanisms of Dementia.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Julia Sala-JarqueMolecular and Cellular Neurobiotechnology Group, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, 08028 Barcelona, Spain.
Karolina ZimkowskaMolecular and Cellular Neurobiotechnology Group, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0001-8912-0671
Jesús ÁvilaCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, 08028 Barcelona, Spain.ORCID 0000-0002-6288-0571
Isidro FerrerCiberned (Network Centre of Biomedical Research of Neurodegenerative Diseases), Institute of Health Carlos III, 08028 Barcelona, Spain.ORCID 0000-0001-9888-8754
José Antonio Del RíoMolecular and Cellular Neurobiotechnology Group, Institute for Bioengineering of Catalonia (IBEC), Parc Científic de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-5214-4909
Instituto de Salud Carlos III · ES

Funding

Commission for Universities and Research of the Department of Innovation, Universities, and Enterprise of the Generalitat de Catalunya SGR2017-648"la Caixa" Foundation (ID 100010434) LCF/PR/HR19/52160007María de Maeztu Unit of Excellence MDM-2017-0729MCIN/AEI/ 10.13039/501100011033 PID2021-123714OB-I00MCIN/AEI/ 10.13039/501100011033 RTI2018-099773-B-I00
6 · The paper itself

Abstract

Tauopathies are a group of neurodegenerative diseases characterized by the hyperphosphorylation and deposition of tau proteins in the brain. In Alzheimer's disease, and other related tauopathies, the pattern of tau deposition follows a stereotypical progression between anatomically connected brain regions. Increasing evidence suggests that tau behaves in a "prion-like" manner, and that seeding and spreading of pathological tau drive progressive neurodegeneration. Although several advances have been made in recent years, the exact cellular and molecular mechanisms involved remain largely unknown. Since there are no effective therapies for any tauopathy, there is a growing need for reliable experimental models that would provide us with better knowledge and understanding of their etiology and identify novel molecular targets. In this review, we will summarize the development of cellular models for modeling tau pathology. We will discuss their different applications and contributions to our current understanding of the "prion-like" nature of pathological tau.

Indexed as

Alzheimer DiseasePrionsTauopathiesBrainHumanstau ProteinsPrionstau Proteinsneurodegenerationseedingspreadingtauopathies

Identifiers

PMID36232835
PMCPMC9570106
OpenAlexW4297982563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.